Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 522

1.

Effects of vatalanib on tumor growth can be potentiated by mTOR blockade in vivo.

Jaeger-Lansky A, Cejka D, Ying L, Preusser M, Hoeflmayer D, Fuereder T, Koehrer S, Wacheck V.

Cancer Biol Ther. 2010 Jun 1;9(11):919-27. Epub 2010 Jun 18.

PMID:
20404549
[PubMed - indexed for MEDLINE]
Free Article
2.

Everolimus (RAD001) and anti-angiogenic cyclophosphamide show long-term control of gastric cancer growth in vivo.

Cejka D, Preusser M, Woehrer A, Sieghart W, Strommer S, Werzowa J, Fuereder T, Wacheck V.

Cancer Biol Ther. 2008 Sep;7(9):1377-85. Epub 2008 Sep 2.

PMID:
18708754
[PubMed - indexed for MEDLINE]
Free Article
3.

mTOR inhibitor RAD001 (everolimus) has antiangiogenic/vascular properties distinct from a VEGFR tyrosine kinase inhibitor.

Lane HA, Wood JM, McSheehy PM, Allegrini PR, Boulay A, Brueggen J, Littlewood-Evans A, Maira SM, Martiny-Baron G, Schnell CR, Sini P, O'Reilly T.

Clin Cancer Res. 2009 Mar 1;15(5):1612-22. doi: 10.1158/1078-0432.CCR-08-2057. Epub 2009 Feb 17.

PMID:
19223496
[PubMed - indexed for MEDLINE]
Free Article
4.

mTOR inhibition sensitizes gastric cancer to alkylating chemotherapy in vivo.

Cejka D, Preusser M, Fuereder T, Sieghart W, Werzowa J, Strommer S, Wacheck V.

Anticancer Res. 2008 Nov-Dec;28(6A):3801-8.

PMID:
19189667
[PubMed - indexed for MEDLINE]
Free Article
5.

The vascular endothelial growth factor receptor tyrosine kinase inhibitors vatalanib and pazopanib potently induce apoptosis in chronic lymphocytic leukemia cells in vitro and in vivo.

Paesler J, Gehrke I, Gandhirajan RK, Filipovich A, Hertweck M, Erdfelder F, Uhrmacher S, Poll-Wolbeck SJ, Hallek M, Kreuzer KA.

Clin Cancer Res. 2010 Jul 1;16(13):3390-8. doi: 10.1158/1078-0432.CCR-10-0232. Epub 2010 Jun 22.

PMID:
20570929
[PubMed - indexed for MEDLINE]
Free Article
6.
7.

Everolimus augments the effects of sorafenib in a syngeneic orthotopic model of hepatocellular carcinoma.

Piguet AC, Saar B, Hlushchuk R, St-Pierre MV, McSheehy PM, Radojevic V, Afthinos M, Terracciano L, Djonov V, Dufour JF.

Mol Cancer Ther. 2011 Jun;10(6):1007-17. doi: 10.1158/1535-7163.MCT-10-0666. Epub 2011 Apr 12.

PMID:
21487053
[PubMed - indexed for MEDLINE]
Free Article
8.

Antitumor effect of the mTOR inhibitor everolimus in combination with trastuzumab on human breast cancer stem cells in vitro and in vivo.

Zhu Y, Zhang X, Liu Y, Zhang S, Liu J, Ma Y, Zhang J.

Tumour Biol. 2012 Oct;33(5):1349-62. doi: 10.1007/s13277-012-0383-6. Epub 2012 Apr 11.

PMID:
22492237
[PubMed - indexed for MEDLINE]
9.

Inhibition of STAT3 signaling pathway by nitidine chloride suppressed the angiogenesis and growth of human gastric cancer.

Chen J, Wang J, Lin L, He L, Wu Y, Zhang L, Yi Z, Chen Y, Pang X, Liu M.

Mol Cancer Ther. 2012 Feb;11(2):277-87. doi: 10.1158/1535-7163.MCT-11-0648. Epub 2011 Dec 27.

PMID:
22203730
[PubMed - indexed for MEDLINE]
Free Article
10.

The antitumor and antiangiogenic activity of vascular endothelial growth factor receptor inhibition is potentiated by ErbB1 blockade.

Sini P, Wyder L, Schnell C, O'Reilly T, Littlewood A, Brandt R, Hynes NE, Wood J.

Clin Cancer Res. 2005 Jun 15;11(12):4521-32.

PMID:
15958638
[PubMed - indexed for MEDLINE]
Free Article
11.

Effects of combined inhibition of MEK and mTOR on downstream signaling and tumor growth in pancreatic cancer xenograft models.

Chang Q, Chen E, Hedley DW.

Cancer Biol Ther. 2009 Oct;8(20):1893-901. Epub 2009 Oct 6.

PMID:
20009539
[PubMed - indexed for MEDLINE]
Free Article
12.

Vascular disruption in combination with mTOR inhibition in renal cell carcinoma.

Ellis L, Shah P, Hammers H, Lehet K, Sotomayor P, Azabdaftari G, Seshadri M, Pili R.

Mol Cancer Ther. 2012 Feb;11(2):383-92. doi: 10.1158/1535-7163.MCT-11-0748. Epub 2011 Nov 14.

PMID:
22084164
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Efficacy of everolimus, a novel mTOR inhibitor, against basal-like triple-negative breast cancer cells.

Yunokawa M, Koizumi F, Kitamura Y, Katanasaka Y, Okamoto N, Kodaira M, Yonemori K, Shimizu C, Ando M, Masutomi K, Yoshida T, Fujiwara Y, Tamura K.

Cancer Sci. 2012 Sep;103(9):1665-71. doi: 10.1111/j.1349-7006.2012.02359.x. Epub 2012 Aug 1.

PMID:
22703543
[PubMed - indexed for MEDLINE]
14.

Combination of vascular endothelial growth factor receptor/platelet-derived growth factor receptor inhibition markedly improves radiation tumor therapy.

Timke C, Zieher H, Roth A, Hauser K, Lipson KE, Weber KJ, Debus J, Abdollahi A, Huber PE.

Clin Cancer Res. 2008 Apr 1;14(7):2210-9. doi: 10.1158/1078-0432.CCR-07-1893.

PMID:
18381963
[PubMed - indexed for MEDLINE]
Free Article
15.

Sustained antitumor activity by co-targeting mTOR and the microtubule with temsirolimus/vinblastine combination in hepatocellular carcinoma.

Zhou Q, Lui VW, Lau CP, Cheng SH, Ng MH, Cai Y, Chan SL, Yeo W.

Biochem Pharmacol. 2012 May 1;83(9):1146-58. doi: 10.1016/j.bcp.2012.01.013. Epub 2012 Jan 20.

PMID:
22285225
[PubMed - indexed for MEDLINE]
16.

Measurement of tumor VEGF-A levels with 89Zr-bevacizumab PET as an early biomarker for the antiangiogenic effect of everolimus treatment in an ovarian cancer xenograft model.

van der Bilt AR, Terwisscha van Scheltinga AG, Timmer-Bosscha H, Schröder CP, Pot L, Kosterink JG, van der Zee AG, Lub-de Hooge MN, de Jong S, de Vries EG, Reyners AK.

Clin Cancer Res. 2012 Nov 15;18(22):6306-14. doi: 10.1158/1078-0432.CCR-12-0406. Epub 2012 Sep 26.

PMID:
23014526
[PubMed - indexed for MEDLINE]
Free Article
17.

Gastric cancer growth control by BEZ235 in vivo does not correlate with PI3K/mTOR target inhibition but with [18F]FLT uptake.

Fuereder T, Wanek T, Pflegerl P, Jaeger-Lansky A, Hoeflmayer D, Strommer S, Kuntner C, Wrba F, Werzowa J, Hejna M, Müller M, Langer O, Wacheck V.

Clin Cancer Res. 2011 Aug 15;17(16):5322-32. doi: 10.1158/1078-0432.CCR-10-1659. Epub 2011 Jun 28.

PMID:
21712451
[PubMed - indexed for MEDLINE]
Free Article
18.

Novel synergistic antitumor effects of rapamycin with bortezomib on hepatocellular carcinoma cells and orthotopic tumor model.

Wang C, Gao D, Guo K, Kang X, Jiang K, Sun C, Li Y, Sun L, Shu H, Jin G, Sun H, Wu W, Liu Y.

BMC Cancer. 2012 May 4;12:166. doi: 10.1186/1471-2407-12-166.

PMID:
22559167
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

The Combination of Sorafenib and Everolimus Abrogates mTORC1 and mTORC2 upregulation in osteosarcoma preclinical models.

Pignochino Y, Dell'Aglio C, Basiricò M, Capozzi F, Soster M, Marchiò S, Bruno S, Gammaitoni L, Sangiolo D, Torchiaro E, D'Ambrosio L, Fagioli F, Ferrari S, Alberghini M, Picci P, Aglietta M, Grignani G.

Clin Cancer Res. 2013 Apr 15;19(8):2117-31. doi: 10.1158/1078-0432.CCR-12-2293. Epub 2013 Feb 22.

PMID:
23434734
[PubMed - indexed for MEDLINE]
Free Article
20.

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk